# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B of A Securities analyst Tazeen Ahmad initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Buy rating and announces P...
Piper Sandler analyst Edward Tenthoff reiterates Sutro Biopharma (NASDAQ:STRO) with a Overweight and lowers the price target...
Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.
Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and lowers the price targe...
JMP Securities analyst Reni Benjamin reiterates Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and maintains $17 pri...
Sutro Biopharma shares are trading lower by 4.3% during Tuesday's session. The company announced the pricing of an underwri...